e-learning
resources
Amsterdam 2011
Sunday, 25.09.2011
Drug delivery and pharmacokinetics I
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Optimization of inhalation treatment – Evaluation of influence of PNEUMOlogic® and Optimiser® spacers on aerosol particle distribution from pMDI-EB
Z. Podolec, J. Siekaniec (Cracow, Poland)
Source:
Annual Congress 2011 - Drug delivery and pharmacokinetics I
Session:
Drug delivery and pharmacokinetics I
Session type:
Thematic Poster Session
Number:
835
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Z. Podolec, J. Siekaniec (Cracow, Poland). Optimization of inhalation treatment – Evaluation of influence of PNEUMOlogic® and Optimiser® spacers on aerosol particle distribution from pMDI-EB. Eur Respir J 2011; 38: Suppl. 55, 835
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Optimization of inhalation treatment – Evaluation of influence of spacer integrated with the spirometer on aerosol particle distribution from pMDI-EB
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010
Optimization of inhalation treatment – Assessment of the influence of diluent and air humidity on particle distribution of colistin administered by BCTS method [bronchial control treatment system]
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010
Evaluation of pulmonary diffusion: TL
CO
or K
CO
?
Source: Annual Congress 2010 - Advances in lung function I
Year: 2010
Comparison between SCOT-15® and Perfadex® as lung preservation solutions
Source: Annual Congress 2011 - Immunobiology in the transplanted lung: experimental and clinical evaluations
Year: 2011
Airway resistances: R
aw
, sR
aw
, sR
eff
– Which is the best determinant of airway function?
Source: Annual Congress 2010 - Lung function from infancy to adulthood
Year: 2010
Usability evaluation of NEXThaler® versus Diskus® and Turbuhaler®
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012
Patient assessments of ease of use of Genuair® versus Aerolizer® and HandiHaler®
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011
Transcutaneous measurement of pCO
2
(p
tc
CO
2
): Time delay from change in alveolar pCO
2
to first response in p
tc
CO
2
Source: Annual Congress 2011 - Sleep and weight: heavy under pressure
Year: 2011
Endogenous particles in exhaled air – Variability of particle number in healthy individuals
Source: Annual Congress 2012 - Airway diseases: from invasive to noninvasive biomarkers
Year: 2012
Evaluation of difficult asthma – a single centre experience
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Ways to shorten the lung clearance index measurement ΙΙ – How long to wash?
Source: Annual Congress 2012 - New developments in paediatric respiratory physiology
Year: 2012
Effective and efficient nebulization of alpha
1
-proteinase inhibitor (alpha
1
-PI) for inhalation therapy using the AKITA
2
® APIXNEBÔ nebulizer system
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010
Sensitivity and specificity of airway hyperreactivity (AHR) based on methacholine challenge (MCH) tests – Comparison of sG
eff
with FEV
1
and MEF
50
as target parameter
Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease
Year: 2012
Clinical decision making in alpha
1
antitrypsin deficiency emphysema – Methodologies to determine individual rates of FEV
1
decline
Source: Annual Congress 2010 - Novel biomarkers and old parameters in approaching pulmonary diseases
Year: 2010
Comparative
in vitro
performance of a new re-usable breath-actuated nebulizer (BAN) with other high performance systems intended for domiciliary use – 2: Portable battery-compressor
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012
Study of the use of Chartis® pulmonary assessment system to optimize subject selection for endobronchial lung volume reduction (ELVR) – Results and subgroup analysis
Source: Annual Congress 2011 - Endoscopic lung volume reduction: hype or hope?
Year: 2011
Evaluation of a new motion sensor in patients with COPD – Preliminary results
Source: Annual Congress 2010 - Physical activity methodology assessment and clinical consequences
Year: 2010
The results of drug resistance survey of MDR-strains on second line drugs obtains in national reference laboratory – " M.Nasta " Institute – Bucharest
Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis
Year: 2011
Patients‘ knowledge about inhalation therapy in pulmology – One year after intervention
Source: Annual Congress 2011 - Medical education
Year: 2011
The
in-vitro
pharmacology of PF-3429281 – A novel inhaled dual antimuscarinic/β
2
adrenoceptor agonist
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept